ORIGINAL ARTICLE

Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid

Grant Theron,1 Jonny Peter,1 Richard Meldau,1 Hoosain Khalfrey,1 Phindile Gina,1 Brian Matinyena,1 Laura Lenders,1 Gregory Calligaro,1 Brian Allwood,1 Gregory Symons,1 Ureshnie Govender,1 Mashiko Setshedhi,1 Keertan Dheda1,2

ABSTRACT

Rationale The accuracy and impact of new tuberculosis (TB) tests, such as Xpert MTB/RIF, when performed on bronchoalveolar lavage fluid (BALF) obtained from patients with sputum-scarce or smear-negative TB is unclear.

Methods South African patients with suspected pulmonary TB (n=160) who were sputum-scarce or smear-negative underwent bronchoscopy. MTB/RIF was performed on uncentrifuged BALF (1 ml) and/or a resuspended pellet of centrifuged BALF (∼10 ml). Time to TB detection and anti-TB treatment initiation were compared between phase one, when MTB/RIF was performed as a research tool, and phase two, when it was used for patient management.

Results 27 of 154 patients with complete data had culture-confirmed TB. Of these, a significantly lower proportion were detected by smear microscopy compared with MTB/RIF (58%, 95% CI 39% to 75% versus 93%, 77% to 98%; p<0.001). Of the 127 patients who were culture negative, 96% (91% to 98%) were MTB/RIF negative. When phase two was compared with phase one, MTB/RIF reduced the median days to TB detection and anti-TB treatment initiation were compared between phase one, when MTB/RIF was performed as a research tool, and phase two, when it was used for patient management.

Conclusions MTB/RIF detected TB cases more accurately and more rapidly than smear microscopy and significantly reduced the rate of empirical treatment.

INTRODUCTION

Tuberculosis (TB) is the leading cause of morbidity and mortality in patients with HIV infection in sub-Saharan Africa. Sputum-based smear microscopy is commonly used to diagnose TB, however its sensitivity is poor (40–60%). In South Africa, patients who are smear negative or sputum scarce represent up to a third of those with pulmonary TB, and these individuals are often at an increased risk of poor outcomes due to the associated delay in making a diagnosis.

Obtaining a high-quality biological specimen for testing is key to reducing the diagnostic delay. Although sputum induction is frequently used, it fails to provide a specimen of adequate volume or quality in up to 20% of cases and does not enable the airways to be visualised or biopsied. Thus, bronchoscopy with bronchoalveolar lavage or bronchial washings is often performed, when available, in patients who are smear negative or sputum scarce.

Newer nucleic acid amplification technologies, such as the World Health Organization (WHO)-endorsed Xpert MTB/RIF assay (Cepheid, USA), represent a significant advance over smear microscopy. However, MTB/RIF still does not detect significant proportions of patients who are smear negative or infected with HIV (sensitivities of 68% and 80%, respectively).

Although the accuracy of MTB/RIF when performed on sputum is well validated, little is known about its performance in bronchoalveolar lavage.
lavage fluid (BALF). There are limited data from a few studies evaluating a small number of specimens, and none from a setting with high HIV prevalence. Furthermore, there is no information regarding whether MTB/RIF testing of BALF can improve the proportion of patients initiating treatment or the time-to-treatment initiation in settings where rates of empirical treatment are high.

To better understand these issues, we prospectively examined the accuracy of MTB/RIF performed on BALF obtained from smear-negative or sputum-scarce patients with suspected pulmonary TB recruited from a hospital in Cape Town, South Africa. We assessed the impact of MTB/RIF on time to diagnosis, the proportion of patients who initiated treatment (overall and empirically), and the time to treatment initiation before (phase one) and after it was used for patient management (phase two).

**MATERIALS AND METHODS**

**Study sites and population**

We prospectively enrolled patients (≥18 years of age) with suspected pulmonary TB who were referred for bronchoscopy to the respiratory clinic at Groote Schuur Hospital in Cape Town, South Africa (n=160; figure 1) between December 2007 and November 2012. Patients had at least one symptom of TB, a chest radiograph with infiltrates compatible with active TB, at least two consecutive sputum smear microscopy results negative for acid-fast bacilli (within 2 weeks of enrolment) or were unable to self-expectorate sputum. A bronchoscopy also had to be judged to be safe and feasible. MTB/RIF results were, prior to the WHO endorsement of the assay for sputum testing in February 2011, not reported to clinical staff and not used for patient management (phase one). Following its endorsement, MTB/RIF was used to guide the initiation of anti-TB treatment (phase two). Aside from the use of MTB/RIF for patient management in phase two, the study conditions, eligibility criteria, and clinical staff were the same in both phases.

**Patient evaluation and specimen collection**

Detailed patient and laboratory-specific information was recorded on a standardised case record form. An HIV test was performed after appropriate counselling. Bronchoscopy was performed by clinical investigators (KD, HK, GS, GC, BA) by placement of the bronchoscope into an airway of an affected lung segment, and the instillation of sterile saline (0.9%), usually to a volume of 60–120 ml. Bronchial brushings and/or a transbronchial biopsy was obtained if technically feasible and appropriate for the clinical investigation of that patient.

**Routine diagnostic tests**

BALF was split and one arbitrarily selected aliquot sent immediately to a reference laboratory attached to Groote Schuur Hospital for NALC-NaOH decontamination. The second aliquot was used for MTB/RIF testing. The decontaminated specimen was examined twice by concentrated fluorescence smear microscopy and underwent liquid culture for *Mycobacterium tuberculosis* using the BACTEC MGIT 960 system (BD Diagnostics, USA). Culture-positive isolates underwent routine phenotypic drug susceptibility testing for rifampicin and isoniazid using the MGIT 960 SIRE kit from December 2008. When requested, concentrated fluorescence smear microscopy and liquid culture were also performed on bronchial brushings and transbronchial biopsy specimens. Histological examination was undertaken on transbronchial biopsies, when available.

**Patient classification**

Patients were classified as definite TB if they had at least one specimen culture positive for TB or, upon histological investigation of the transbronchial biopsy, were reported to contain caseating or necrotising granulomatous inflammation compatible with TB. Patients who were BALF culture negative for TB and had no histological evidence of active TB disease were classified either as possible TB (if initiated on anti-TB treatment based on clinical suspicion) or as non-TB (if not initiated on anti-TB treatment). A patient was empirically treated if treatment was initiated by the attending physician in the absence of a positive test result (further details on empirical treatment initiation is given in the online supplementary material).

**Xpert MTB/RIF and patient management**

An aliquot of BALF was either frozen at −20°C for later batched testing in phase one, or used immediately for MTB/RIF testing in phase two. Thus, in phase two, MTB/RIF was used to guide patient management whereas in phase one it was performed for research use only, and treatment was guided by smear microscopy and culture. The assay was performed on 1 ml of uncentrifuged BALF and, when available, a median volume (IQR) of 10 ml (5–10) of BALF centrifuged (3000×g, 15 min) at room temperature and, following decantation of the supernatant, resuspended in 1 ml of sterile phosphate-buffered saline. The MTB/RIF procedure was then followed as described. The laboratory technician performing the procedure was blinded to patient information and test results. MTB/RIF results in phase two were reported immediately to clinical staff.

**Analysis of discordant Xpert MTB/RIF and culture results**

When sufficient BALF remained, a Genotype MTBDRplus assay (version two; Hain Lifesciences) was performed on specimens that where either MTB/RIF positive but culture and histology negative for active TB; or specimens that were MTB/RIF positive for *M tuberculosis* complex and rifampicin resistant, but had phenotypically susceptible culture isolates.

**Statistical analysis**

We followed the STARD criteria. For the primary analysis of MTB/RIF sensitivity and specificity on BALF, culture positivity from the same specimen served as a reference standard. A secondary analysis was performed versus culture positivity from any specimen and/or a histological profile compatible for active TB. A third analysis was also performed when the possible TB group was included in the definite TB group. Statistical analyses were performed using OpenEpi (V.2.3.1) and Graphpad Prism (V5.0; GraphPad Software, USA, http://www.graphpad.com). We used the D’Agostino–Pearson omnibus test to detect for normality. The Mann–Whitney test was used to compare non-parametric median time to detection or treatment. The Mid-P exact test was used for comparisons between proportions. CIs were calculated using the Wilson Score method.

**RESULTS**

**Study population and TB diagnoses**

Of the 160 patients with suspected pulmonary TB who were referred for bronchoscopy and consented to participate in the study, six were excluded from the analysis as indicated in figure 1. Of the 154 included patients, 111 (72%) were sputum scarce and 46 (33%) were HIV infected (table 1). Twenty-seven of the 154 patients (18%) were BALF culture positive for *M tuberculosis*. When a bronchial brushing or transbronchial biopsy was cultured,
9/39 (23%) and 4/15 (26%) of patients were positive, respectively.

All culture-positive bronchial brushings and biopsies also had culture-positive BALF. Histological examination of transbronchial biopsies showed compatibility with active TB in 7 of the 102 cases (7%) examined, with only one having culture-negative BALF. A greater proportion of culture-negative cases had a history of previous TB treatment compared with those with definite TB (39% vs 18%; p=0.031). The clinical, demographic and diagnostic characteristics of patients were similar across both phases (see online supplementary table S1).
Diagnostic accuracy of MTB/RIF performed on uncentrifuged BALF

Of the 27 culture-positive patients, 25 had MTB/RIF-positive uncentrifuged BALF. The sensitivity of MTB/RIF was 93% (25/27; 95% CI 77% to 98%) and significantly higher than smear microscopy performed on the same fluid, which had a sensitivity of 58% (15/26; 39% to 75%; p<0.001; table 2). Five of 127 culture-negative cases had MTB/RIF-positive uncentrifuged BALF, resulting in a specificity of 96% (91% to 98%), which was similar to smear microscopy (99% (126/127; 96% to 100%); p=0.121). The positive predictive value (PPV) and negative predictive value (NPV) of MTB/RIF were 83% (25/30; 67% to 93%) and 98% (120/122; 94% to 100%), respectively. HIV coinfection did not impact sensitivity, specificity (table 2) or liquid culture time to positivity (TTP). When MTB/RIF accuracy was evaluated using a composite reference standard (culture positivity from any specimen and/or histological evidence of active TB from a transbronchial biopsy), the sensitivity and specificity were similar to those obtained in the primary analysis using either definite TB versus possible and non-TB combined (see online supplementary table S2); definite and possible TB combined versus non-TB (see online supplementary table S3); or definite TB versus non-TB with the possible TB group excluded (see online supplementary table S4).

Effect of BALF centrifugation on MTB/RIF accuracy

Of the 100 patients with BALF available for centrifugation, 19 were culture positive for TB. Centrifugation did not improve sensitivity and high specificity was retained (table 2), and did not affect C_{1} values (see online supplementary material).

Analysis of patients who were MTB/RIF positive with no culture or histological evidence of active TB

We detected 12 MTB/RIF-positive, culture-negative results (from 11 patients). Five of the eleven patients had sufficient BALF stored for a Genotype MTBDR plus assay, the specimens of which were all detected as containing M tuberculosis complex DNA. When these five patients were added to the definite TB group, the sensitivity and specificity of an uncentrifuged MTB/RIF changed from 92.6% (25/27) and 96% (120/125) to 94% (30/32) and 100% (120/120), respectively. Further clinical information about the patients who were MTB/RIF positive, culture negative is given in the online supplementary material.

Relationship of MTB/RIF-generated cycle threshold values with bacterial load

MTB/RIF-generated C_{1} values had a strong correlation with smear grade (p=0.008) and liquid culture TTP (p=0.001; R^2=0.49) (figure 2).

Accuracy of MTB/RIF for the detection of resistance to rifampicin

BALF from four patients was detected as resistant to rifampicin. One was culture positive and phenotypically resistant to rifampicin and isoniazid. The remaining three were culture negative and did not have phenotypic drug susceptibility data. Of these, one had sufficient BALF fluid remaining for a Genotype MTBDR plus assay, and was M tuberculosis complex positive but rifampicin and isoniazid susceptible. Of the three, two completed standard first-line treatment and one was not placed on treatment. All had symptoms resolved at follow-up.

Impact of MTB/RIF on time to TB detection (phase one vs phase two)

The time-point-specific proportions of definite TB cases detected by MTB/RIF (uncentrifuged and centrifuged), smear microscopy (on any specimen), histology and liquid culture are shown in figure 3 for phase two when MTB/RIF was used for patient management. Eighteen definite TB cases were detected. The median time to detection (IQR) for MTB/RIF was 0 days (0–0), compared with 0 days (0–1) for smear microscopy, 3 days (1–10) for histology and 15 days (11–20) for liquid culture (p values of 0.229, 0.001 and <0.001, respectively compared with MTB/RIF). The median (IQR) time to detection for smear-negative TB shortened from 29 days (18–41) to 0 days (0–0; p<0.001) (all smear-negative TB cases were detected by MTB/RIF in phase two) (table 3).

Impact of Xpert MTB/RIF on the proportion of patients initiating anti-TB treatment (phase one vs phase two)

Table 3 and figure 4 summarise differences in treatment initiation between the two phases. Overall, a similar proportion of patients were initiated on anti-TB treatment when phase one was compared with phase two (26% (17/67) vs 36% (26/73); p=0.196). Of those initiated onto treatment, a similar proportion were confirmed TB cases (41% (7/17) for phase one vs 68% (15/23) for phase two; p=0.150). The proportion of patients initiating treatment in each phase based on the results of smear microscopy, histology, MTB/RIF, culture or clinical and
<table>
<thead>
<tr>
<th>Table 2</th>
<th>Accuracy of Xpert MTB/RIF for the detection of culture-positive TB in bronchoalveolar lavage fluid</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All patients n=154</td>
</tr>
<tr>
<td></td>
<td>Sensitivity, % (95% CI)</td>
</tr>
<tr>
<td>Smear microscopy</td>
<td>57.7 (39 to 74.5)</td>
</tr>
<tr>
<td></td>
<td>15/26</td>
</tr>
<tr>
<td>MTB/RIF performed on uncentrifuged BALF</td>
<td>92.6 (76.7 to 98.0)</td>
</tr>
<tr>
<td></td>
<td>25/27 (p=0.001)</td>
</tr>
<tr>
<td>MTB/RIF performed on uncentrifuged BALF in patients who were smear negative</td>
<td>81.9 (52.4 to 94.9)</td>
</tr>
<tr>
<td></td>
<td>9/11</td>
</tr>
<tr>
<td>MTB/RIF performed on a resuspended pellet of centrifuged BALF</td>
<td>94.8 (75.4 to 99.1)</td>
</tr>
<tr>
<td></td>
<td>18/19</td>
</tr>
<tr>
<td>Two MTB/RIF assays (performed on uncentrifuged and centrifuged BALF, respectively)</td>
<td>100 (83.2 to 100)</td>
</tr>
<tr>
<td></td>
<td>19/19</td>
</tr>
<tr>
<td>PPV† (95% CI)</td>
<td>93.8 (71.7 to 98.9)</td>
</tr>
<tr>
<td></td>
<td>15/16</td>
</tr>
<tr>
<td>NPV† (95% CI)</td>
<td>92 (86.2 to 95.5)</td>
</tr>
<tr>
<td></td>
<td>12/15</td>
</tr>
<tr>
<td>MTB/RIF performed on uncentrifuged BALF in patients who were smear negative</td>
<td>98.4 (94.3 to 99.6)</td>
</tr>
<tr>
<td></td>
<td>9/13</td>
</tr>
<tr>
<td>MTB/RIF performed on a resuspended pellet of centrifuged BALF</td>
<td>98.7% (92.9 to 99.8)</td>
</tr>
<tr>
<td></td>
<td>74/75</td>
</tr>
<tr>
<td>Two MTB/RIF assays (performed on uncentrifuged and centrifuged BALF, respectively)</td>
<td>70.4 (51.6 to 84.2)</td>
</tr>
<tr>
<td></td>
<td>19/27</td>
</tr>
</tbody>
</table>

*Based on TB prevalences of 18%, 14% and 18% overall and in the patient groups with HIV infection and without HIV infection.
BALF, bronchoalveolar lavage fluid; NPV, negative predictive value; PPV, predictive value; TB, tuberculosis.
radiological findings alone (empirical treatment) is shown in figure 4A and B. In phase two, a smaller proportion of the patients were initiated empirically (79% (11/14) vs 28% (10/25); p=0.026) and the proportion of patients who initiated treatment on the basis of a positive rapid test result (smear microscopy in phase one with the addition of MTB/RIF in phase two) increased from 14% (2/14) to 80% (20/25; p<0.001).

Of those treated on empirical grounds, 25% (7/17) and 58% (15/26) were later shown to be definite TB from a specimen collected at recruitment in phase one and phase two (p=0.312). The median time to empirical TB treatment initiation did not differ in phase one versus phase two (2 (1–24) days vs 40 (10–79) days; p=0.071).

Impact of Xpert MTB/RIF on the time to anti-TB treatment initiation (phase one vs phase two)
The median (IQR) times to anti-TB treatment initiation for phase one and phase two when MTB/RIF was used for patient management were 10 (1–49) days and 7 (0–21) days, respectively (p=0.330) (figure 5). For patients with definite TB, these times were 5 (1–57) and 2 (0–7) days, respectively (p=0.358). For smear-negative patients, the median times to treatment initiation across each phase were 15 (1–50) days and 7 (0–33) days, respectively (p=0.55). When the time-specific proportion of patients initiating anti-TB treatment was compared at time points of 2, 10, 20, 30, 40 and 50 days, there were no differences detected.

DISCUSSION
Information regarding the accuracy and impact of MTB/RIF when performed on BALF is limited. The effect of HIV infection, specimen concentration and impact on time to TB diagnosis and treatment initiation is unknown. Bronchoscopy is used frequently, when appropriate, in major cities in South Africa. In the Western Cape Province there are around eight hospitals (public and private facilities) with bronchoscopy facilities. In public healthcare facilities in Cape Town around 600 bronchoscopies are performed each year. The key findings of our study are as follows: MTB/RIF significantly outperformed smear microscopy on BALF, improved the time to diagnosis and detected ≥80% of TB cases that were smear negative; centrifugation did not improve accuracy; empirical treatment was higher with smear microscopy as the only available rapid test; and hence MTB/RIF did not significantly impact the overall proportion of patients initiating treatment. Our study highlights the possibility that the impact of MTB/RIF may be overestimated due to high rates of empirical treatment when smear microscopy is the only available rapid test.

Four studies examined MTB/RIF performance in BALF and all possessed a small number of specimens, were conducted retrospectively on biobanked specimens, and had less than five TB cases. In our study of 154 patients, the sensitivity of MTB/RIF on BALF was 94%, similar to other respiratory specimens, and exceeded that reported for other commercially available nucleic acid amplification tests. We detected 11 patients who were MTB/RIF positive and culture

Figure 3  Time-specific proportion of definite TB cases detected by different diagnostic methods when MTB/RIF results were used for patient management in phase two.

*Positive results are included here from different specimens for smear microscopy: of all 12 smear-positives, two did not have smear-positive bronchoalveolar lavage fluid but did have smear-positive bronchial biopsies. Histology was only performed on bronchial biopsies in 12 of the 18 definite TB cases. For liquid culture, all 17 detected individuals had culture-positive bronchoalveolar lavage fluid and there were no additional cases detected on bronchial brushings and biopsies. MTB/RIF was performed only on bronchoalveolar lavage fluid.

negative. We have previously demonstrated that such patients likely represent true TB cases.\textsuperscript{25}

Similar to what has previously been documented in sputum,\textsuperscript{25, 26} we found that MTB/RIF-generated quantitative information strongly correlated with markers of bacterial load in BALF, such as smear grade and liquid culture TTP. This has implications for the use of MTB/RIF C\textsubscript{T} values to assess disease severity,\textsuperscript{27} identify those at risk of treatment failure\textsuperscript{28–30} and stratify patients likely to be highly infectious.\textsuperscript{31}

Previously we demonstrated that the use of 5–10 ml of centrifuged urine from HIV-infected sputum-scarce individuals improved MTB/RIF performance compared with uncentrifuged urine.\textsuperscript{22}

**Figure 4** Venn diagrams (A) and bar graph (B) showing the proportion of patients either initiated onto treatment on the basis of different positive test results, or who treated empirically in the absence of a positive result before (phase one) and after (phase two) Xpert MTB/RIF was used for patient management. Two percent of 64 patients in phase one and 35% of patients in phase two were placed on treatment and have known dates of treatment initiation. Three patients in phase one and one patient in phase two who were placed on anti-TB treatment were missing the date of anti-TB treatment initiation and are omitted. Histology detected no patients in phase one and seven patients in phase two (all of which were initiated onto treatment before the histology result was available as they were also smear- or MTB/RIF-positive).

\*Empirical anti-TB treatment is defined as the initiation of treatment on clinical grounds in the absence of positive smear microscopy, histology or culture result (in phase one), plus the absence of a positive MTB/RIF result (phase two only), at time of treatment initiation. Three patients in phase one and one patient in phase two did not have information present regarding the date of treatment initiation.

TB, tuberculosis; IQR, interquartile range.

**Table 3** Impact of MTB/RIF on the times to TB detection and initiation of anti-TB treatment before (phase one) and after (phase two) it was used for patient management

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Phase one</th>
<th>Phase two</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days-to-result (IQR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Definite TB</td>
<td>6 (1–29)</td>
<td>0 (0–1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smear-negative TB</td>
<td>29 (18–41)</td>
<td>0 (0–0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Proportion on treatment (positive over total; %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Definite TB</td>
<td>26 (17/67)</td>
<td>36 (26/73)</td>
<td>0.196</td>
</tr>
<tr>
<td>Smear-negative TB</td>
<td>79 (11/14)</td>
<td>28 (10/25)</td>
<td>0.026</td>
</tr>
<tr>
<td>Proportion of all patients in each phase who initiated treatment according to final microbiological diagnosis (positive over total; %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Definite TB</td>
<td>41 (7/17)</td>
<td>68 (15/23)</td>
<td>0.150</td>
</tr>
<tr>
<td>Smear-negative TB</td>
<td>59 (10/17)</td>
<td>42 (11/26)</td>
<td>0.313</td>
</tr>
<tr>
<td>Days to treatment initiation (IQR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td>10 (1–49)</td>
<td>4 (0–16)</td>
<td>0.330</td>
</tr>
<tr>
<td>Definite TB</td>
<td>5 (1–57)</td>
<td>2 (0–7)</td>
<td>0.358</td>
</tr>
</tbody>
</table>

\*Empirical anti-TB treatment is defined as the initiation of treatment on clinical grounds in the absence of positive smear microscopy, histology or culture result (in phase one), plus the absence of a positive MTB/RIF result (phase two only), at time of treatment initiation. Three patients in phase one and one patient in phase two did not have information present regarding the date of treatment initiation.

\*Empiric anti-TB treatment is defined as the initiation of treatment on clinical grounds in the absence of positive smear microscopy, histology or culture result (in phase one), plus the absence of a positive MTB/RIF result (phase two only), at time of treatment initiation. Three patients in phase one and one patient in phase two did not have information present regarding the date of treatment initiation.
Figure 5 Time-specific proportion of patients initiating anti-TB treatment before (phase one) and after (phase two) MTB/RIF was used for patient management.

We did not find a significant improvement in sensitivity when a similar volume of BALF was centrifuged. This is likely because the concentration of bacilli in fluid sampled directly from the site of disease (the lung) is above the limit of detection of the assay without the need for centrifugation. One millilitre of uncentrifuged BALF is sufficient for accurate performance of the MTB/RIF assay.

Only two studies have, to the best of our knowledge, examined the impact of MTB/RIF on time to TB diagnosis and TB treatment initiation; however, they were performed on sputum. We found MTB/RIF to provide a result in significantly more patients than smear microscopy, and within a similar timeframe (0–1 days), thereby significantly reducing the time to diagnosis in patients with smear-negative BALF.

Although MTB/RIF implementation facilitated a more rapid diagnosis of TB, it did not result in detectable improvements in the time to TB treatment initiation. This is because our study was underpowered to detect small differences in this outcome (sample size calculations suggest that we had 77% power to detect a 20% difference in the proportion initiating treatment between study phases and only a 30% power to detect a difference of 3 days in the time to treatment initiation). This arose due to MTB/RIF becoming the standard care at the study site follow-ence of 3 days in the time to treatment initiation). This arose due to MTB/RIF becoming the standard care at the study site follow-

In summary, MTB/RIF on the BALF of patients who are smear negative or sputum scarce has shown excellent performance for the detection of TB in a HIV-prevalent setting. Although in patients with smear-negative BALF the time to TB result significantly improved, this did not translate into a higher proportion of patients initiating treatment. However, it did reduce the proportion of patients initiating treatment on empirical grounds. The high baseline levels of empirical treatment in our setting may undermine the potential impact of MTB/RIF, but this requires prospective investigation.

ACKNOWLEDGEMENTS

The authors are indebted to the patients who participated in this study, as well as Sister Marietjie Pretorius, Ms Dolphina Cogill and Ms Vonntsa Louw for excellent support.

CONTRIBUTIONS

Conception and design: GT, JP, HK, KD. Specimen collection and clinical input: KD, GC, GS, RM, PG, BM, BA and LL. Analysis and interpretation: GT, JP, KD, GC, MS and UG. Drafting the manuscript for important intellectual content: GT, JP, GC, MS and KD.

FUNDING

This work was supported by an EU-FP7 award (TBSurgent F3-2008-223340). GT, JP and UG are supported by the EDCTP (TB-NEAT) (IP09.32040.009), the South African National Research Foundation (GT, UG), the Claude Leon Foundation (GT) and a Wellcome Trust Training Fellowship (GT). JP is supported by a Discovery Foundation Fellowship, the Fogarty International Clinical Research Scholars/Fellows Support Centre National Institutes of Health grant R24TW007988 and SATBAT (JP). KD is supported by the EDCTP (TB-NEAT, TESA) and the SA DST and NRF (SARChI).

COMPETING INTERESTS

None.

PATIENT CONSENT

Patient consent provided written informed consent for study participation.

ETHICS APPROVAL

The study protocol was approved by the University of Cape Town Faculty of Health Sciences Research Ethics Committee (#421/2006).

PROVENANCE AND PEER REVIEW

Not commissioned; externally peer reviewed.

REFERENCES


Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid

Grant Theron, Jonny Peter, Richard Meldau, Hoosain Khalfey, Phindile Gina, Brian Matinyena, Laura Lenders, Gregory Calligaro, Brian Allwood, Gregory Symons, Ureshnie Govender, Mashiko Setshed and Keertan Dheda

Thorax 2013 68: 1043-1051 originally published online June 29, 2013
doi: 10.1136/thoraxjnl-2013-203485

Updated information and services can be found at: http://thorax.bmj.com/content/68/11/1043

These include:

Supplementary Material
Supplementary material can be found at: http://thorax.bmj.com/content/suppl/2013/07/03/thoraxjnl-2013-203485.DC1

References
This article cites 31 articles, 14 of which you can access for free at: http://thorax.bmj.com/content/68/11/1043#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Cardiothoracic surgery (676)
Drugs: infectious diseases (968)
HIV/AIDS (194)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/